Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis
| Autor: | E.M.G. Jacobs, Frank P. J. Peters, Vivianne C. G. Tjan-Heijnen, Agnes J. van de Wouw, Nelly Peer, Annette W.G. van der Velden, M. Wouter Dercksen, Jacqueline M. Stouthard, Birgit E.P.J. Vriens, Maureen J.B. Aarts, Caroline M.P.W. Mandigers, Jolien Tol, Tineke J. Smilde, Laurence J. C. van Warmerdam, Carin C.D. van der Rijt, Maaike de Boer |
|---|---|
| Přispěvatelé: | Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Medical Oncology |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Cancer Research
PHARMACOKINETICS Neutrophils medicine.medical_treatment MULTICENTER Docetaxel Gastroenterology PEGFILGRASTIM 0302 clinical medicine Breast cancer hemic and lymphatic diseases Granulocyte Colony-Stimulating Factor Randomized Controlled Trials as Topic RISK Neutrophil General Medicine Middle Aged Granulocyte colony-stimulating factor Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Absolute neutrophil count Female Taxoids Granulocyte colony-stimulating factor prophylaxis Pegfilgrastim medicine.drug Adult medicine.medical_specialty INDUCED FEBRILE NEUTROPENIA CELL LUNG-CANCER Antineoplastic Agents Breast Neoplasms Neutropenia 1ST 03 medical and health sciences All institutes and research themes of the Radboud University Medical Center SDG 3 - Good Health and Well-being White blood cell Internal medicine medicine Humans Chemotherapy Aged business.industry medicine.disease PHASE-III PREVENTION Surgery Blood Cell Count Clinical Trials Phase III as Topic business Febrile neutropenia 030215 immunology |
| Zdroj: | Oncology, 93(5), 323-328. Karger Oncology (Basel), 93(5), 323-328. Karger Oncology (Basel: 1948), 93, 323-328 Oncology (Basel: 1948), 93, 5, pp. 323-328 |
| ISSN: | 0030-2414 |
| Popis: | Objective: The primary outcome of the current study is, whether there is a protective effect of prior chemotherapy or of prior granulocyte colony-stimulating factor (G-CSF) on the next cycle blood cell counts. Methods: Hematologic toxicity was evaluated, based on a randomized phase III study in breast cancer patients (n = 167) with >20% risk of febrile neutropenia. The primary endpoint was the nadir blood cell counts for patients treated with G-CSF given during all 6 chemotherapy cycles or limited to the first 2 chemotherapy cycles only. Results: For the present analyses, 47 patients were eligible. In the G-CSF 1-6 arm, the median white blood cell count (WBC) and absolute neutrophil count (ANC) nadir slowly decreased from 10.8 × 109/L in cycle 1 to 7.5 × 109/L in cycle 6 and from 7.1 × 109/L to 5.5 × 109/L, respectively. The median WBC nadir in the G-CSF 1-2 arm decreased from 1.2 × 109/L in cycle 3 to 0.9 × 109/L in cycle 6 and the ANC nadir showed a grade 4 neutropenia of 0.1 × 109/L in cycles 3-6. All patients had ANC recovery to normal levels (≥1.5 × 109/L) without delay on day 1 of the next cycle. Conclusion: We conclude that there is no protective effect of prior G-CSF or prior chemotherapy use on nadir blood cell counts in subsequent cycles. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|